Literature DB >> 31361605

Napsin-A and AMACR are Superior to HNF-1β in Distinguishing Between Mesonephric Carcinomas and Clear Cell Carcinomas of the Gynecologic Tract.

Jennifer Pors1,2, Sheila Segura3, Angela Cheng4, Jennifer X Ji1,2, Basile Tessier-Cloutier1,2, Dawn Cochrane5, Daniel J Fix3, Kay Park3, Blake Gilks1,2,4, Lynn Hoang1,2,4.   

Abstract

Mesonephric carcinoma is a rare gynecologic neoplasm commonly mistaken for clear cell carcinoma, because of their overlapping morphologic features. Both tumors are negative for estrogen receptor and p16, magnifying this diagnostic dilemma. Recently, hepatocyte nuclear factor-1 beta (HNF-1β), a marker for clear cell carcinoma, has also been shown to be positive in mesonephric carcinomas. Other more recent markers for clear cell carcinoma, however, such as Napsin-A and alpha-methylacyl-CoA racemase (AMACR), have not yet been studied in mesonephric carcinomas. Here we examine HNF-1β, AMACR, and Napsin-A immunohistochemistry in 18 mesonephric and 55 endometrial/cervical clear cell carcinomas. HNF-1β was considered positive if nuclear staining was present in ≥70% of cells and at least moderate intensity; for Napsin-A and AMACR, any cytoplasmic staining was considered positive (≥1%). H-scores were determined by multiplying the intensity score by proportion score. HNF-1β was positive in a substantial portion of mesonephric carcinomas (9/18, 50%; H-score 98) and clear cell carcinomas (34/55, 62%; H-score 163) and did not distinguish between the 2 entities (specificity, 50%; P-value of H-score=0.08). Napsin-A and AMACR expression was significantly higher in clear cell [43/55 (78%) and 41/55 (75%), respectively] than mesonephric carcinomas [4/18 (22%) and 4/18 (22%) respectively], and helpful in this differential (specificity: 78% and 78%; P<0.05 for both). When Napsin-A and AMACR staining were seen in mesonephric carcinomas, staining was focal (≤5%), whereas staining in clear cell carcinomas was patchy/diffuse. In summary, Napsin-A and AMACR are helpful in distinguishing mesonephric carcinomas from clear cell carcinomas of the female genital tract, but HNF-1β is not.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31361605      PMCID: PMC6987010          DOI: 10.1097/PAI.0000000000000801

Source DB:  PubMed          Journal:  Appl Immunohistochem Mol Morphol        ISSN: 1533-4058


  38 in total

1.  Prevalence of human papillomavirus DNA in different histological subtypes of cervical adenocarcinoma.

Authors:  E C Pirog; B Kleter; S Olgac; P Bobkiewicz; J Lindeman; W G Quint; R M Richart; C Isacson
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

2.  Utility of α-methylacyl-coenzyme-A racemase (p504s) immunohistochemistry in distinguishing endometrial clear cell carcinomas from serous and endometrioid carcinomas.

Authors:  Oluwole Fadare; Vinita Parkash; Katja Gwin; Krisztina Z Hanley; Elke A Jarboe; Sharon X Liang; Charles M Quick; Wenxin Zheng; Kojo R Rawish; Jonathan L Hecht; Mohamed M Desouki
Journal:  Hum Pathol       Date:  2013-10-10       Impact factor: 3.466

3.  Hormone receptor-negative, thyroid transcription factor 1-positive uterine and ovarian adenocarcinomas: report of a series of mesonephric-like adenocarcinomas.

Authors:  Marie McFarland; Charles M Quick; W Glenn McCluggage
Journal:  Histopathology       Date:  2016-01-04       Impact factor: 5.087

4.  Utility of alpha-methylacyl coenzyme A racemase (p504s antibody) as a diagnostic immunohistochemical marker for cancer.

Authors:  Aziza Nassar; Mahul B Amin; Deborah G Sexton; Cynthia Cohen
Journal:  Appl Immunohistochem Mol Morphol       Date:  2005-09

5.  Alpha-methylacyl-CoA racemase (AMACR) expression in epithelial ovarian cancer.

Authors:  Aurelia Noske; Anne-Katrin Zimmermann; Rosmarie Caduff; Zsuzsanna Varga; Daniel Fink; Holger Moch; Glen Kristiansen
Journal:  Virchows Arch       Date:  2011-06-04       Impact factor: 4.064

6.  A Comparison of GATA3, TTF1, CD10, and Calretinin in Identifying Mesonephric and Mesonephric-like Carcinomas of the Gynecologic Tract.

Authors:  Jennifer Pors; Angela Cheng; Joyce M Leo; Mary A Kinloch; Blake Gilks; Lynn Hoang
Journal:  Am J Surg Pathol       Date:  2018-12       Impact factor: 6.394

7.  Malignant mesonephric tumors of the female genital tract: a clinicopathologic study of 9 cases.

Authors:  Silvia Bagué; Ingrid M Rodríguez; Jaime Prat
Journal:  Am J Surg Pathol       Date:  2004-05       Impact factor: 6.394

Review 8.  Mesonephric adenocarcinoma of the uterine corpus: a case report and review of the literature.

Authors:  Yoji Wani; Kenji Notohara; Choutatsu Tsukayama
Journal:  Int J Gynecol Pathol       Date:  2008-07       Impact factor: 2.762

Review 9.  Malignant mesonephric neoplasms of the uterine cervix. A report of eight cases, including four with a malignant spindle cell component.

Authors:  P B Clement; R H Young; P Keh; A G Ostör; R E Scully
Journal:  Am J Surg Pathol       Date:  1995-10       Impact factor: 6.394

10.  Frequent expression of napsin A in clear cell carcinoma of the endometrium: potential diagnostic utility.

Authors:  Oluwole Fadare; Mohamed M Desouki; Katja Gwin; Krisztina Z Hanley; Elke A Jarboe; Sharon X Liang; Charles M Quick; Wenxin Zheng; Vinita Parkash; Jonathan L Hecht
Journal:  Am J Surg Pathol       Date:  2014-02       Impact factor: 6.394

View more
  3 in total

1.  Mesonephric-Like Adenocarcinoma of Uterine Corpus: A Clinicopathological and Targeted Genomic Profiling Study in a Single Institution.

Authors:  Tianshi Ma; Mengyu Chai; Huafeng Shou; Guoqing Ru; Ming Zhao
Journal:  Front Oncol       Date:  2022-07-05       Impact factor: 5.738

2.  Mesonephric-like Adenocarcinoma of the Ovary: Clinicopathological and Molecular Characteristics.

Authors:  Hyun Hee Koh; Eunhyang Park; Hyun-Soo Kim
Journal:  Diagnostics (Basel)       Date:  2022-01-27

Review 3.  New Pathological and Clinical Insights in Endometrial Cancer in View of the Updated ESGO/ESTRO/ESP Guidelines.

Authors:  Angela Santoro; Giuseppe Angelico; Antonio Travaglino; Frediano Inzani; Damiano Arciuolo; Michele Valente; Nicoletta D'Alessandris; Giulia Scaglione; Vincenzo Fiorentino; Antonio Raffone; Gian Franco Zannoni
Journal:  Cancers (Basel)       Date:  2021-05-26       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.